VBIV vs. RLYB, ALRN, ELDN, BTAI, CKPT, VHAQ, AFMD, LTRN, MNOV, and LPTX
Should you be buying VBI Vaccines stock or one of its competitors? The main competitors of VBI Vaccines include Rallybio (RLYB), Aileron Therapeutics (ALRN), Eledon Pharmaceuticals (ELDN), BioXcel Therapeutics (BTAI), Checkpoint Therapeutics (CKPT), Viveon Health Acquisition (VHAQ), Affimed (AFMD), Lantern Pharma (LTRN), MediciNova (MNOV), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
Rallybio (NASDAQ:RLYB) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
Rallybio has higher earnings, but lower revenue than VBI Vaccines.
90.3% of Rallybio shares are held by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are held by institutional investors. 7.4% of Rallybio shares are held by company insiders. Comparatively, 10.4% of VBI Vaccines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Rallybio has a net margin of 0.00% compared to Rallybio's net margin of -881.79%. VBI Vaccines' return on equity of -66.59% beat Rallybio's return on equity.
Rallybio presently has a consensus target price of $12.20, suggesting a potential upside of 630.54%. Given VBI Vaccines' higher possible upside, analysts clearly believe Rallybio is more favorable than VBI Vaccines.
VBI Vaccines received 467 more outperform votes than Rallybio when rated by MarketBeat users. Likewise, 74.40% of users gave VBI Vaccines an outperform vote while only 73.33% of users gave Rallybio an outperform vote.
Rallybio has a beta of -1.63, suggesting that its share price is 263% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.
In the previous week, VBI Vaccines had 2 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for VBI Vaccines and 2 mentions for Rallybio. VBI Vaccines' average media sentiment score of 0.93 beat Rallybio's score of 0.72 indicating that Rallybio is being referred to more favorably in the media.
Summary
Rallybio and VBI Vaccines tied by winning 7 of the 14 factors compared between the two stocks.
Get VBI Vaccines News Delivered to You Automatically
Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VBIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
VBI Vaccines Competitors List
Related Companies and Tools